Latanoprost

Gland Pharma receives USFDA approval for Latanoprost Ophthalmic Solution, 0.005%, bioequivalent to Xalatan, for treating high eye pressure/intraocular pressure. Expected launch in FY25 with estimated US sales of USD 111.6 million.

Gland Pharma received FDA approval for latanoprost ophthalmic solution, 0.005% (2.5 mL Fill), bioequivalent to Xalatan, used for high eye pressure/intraocular pressure. Expected to launch in FY25, with US sales of ~USD 111.6 million by December 2023.

Gland Pharma secures US FDA approval for Latanoprost Ophthalmic Solution, targeting high intraocular pressure in glaucoma and ocular hypertension patients. The product is bioequivalent to Xalatan and plans to launch in FY 2025. US sales reached $111.6 million in 2023.

Gland Pharma Limited received USFDA approval for Latanoprost Ophthalmic Solution, 0.005% (2.5 mL Fill), bioequivalent to Xalatan, treating high intraocular pressure in glaucoma or ocular hypertension patients. The product segment generated $111.6 million in US sales for the twelve months ending December 2023. Gland Pharma plans to launch the product through marketing partners in fiscal year 2025, aiming to strengthen its position in the US pharmaceutical market.

80% of glaucoma patients on prostaglandin analogs (PGAs) have Grade 2-3 meibomian gland dysfunction (MGD), worsening ocular surface disease (OSD). Benzalkonium chloride (BAK) in chronic drops disrupts tear film stability. Symptoms like redness and tearing can lead to poor medication compliance and glaucoma progression. Innovative non-preserved or non-BAK glaucoma medications, sustained-release drug delivery systems, and non-drug treatments like selective laser trabeculoplasty (SLT) or minimally invasive glaucoma surgeries (MIGS) offer solutions. Preservative-free drops and procedural interventions aim to mitigate MGD and OSD effects.